Loading...
XSHG
600222
Market cap602mUSD
Jul 10, Last price  
7.41CNY
1D
0.27%
1Q
2.21%
Jan 2017
-11.58%
Name

Henan Taloph Pharmaceutical Stock Co Ltd

Chart & Performance

D1W1MN
XSHG:600222 chart
P/E
68.29
P/S
2.33
EPS
0.11
Div Yield, %
0.24%
Shrs. gr., 5y
0.23%
Rev. gr., 5y
4.40%
Revenues
1.76b
-9.46%
364,543,000371,161,000612,738,000813,144,000913,303,000980,782,0001,089,130,6071,304,674,9151,254,230,2361,017,380,811953,306,5131,168,390,5381,194,794,3471,311,814,8171,417,097,3111,604,516,9391,960,694,3082,069,908,7351,941,420,1111,757,789,761
Net income
60m
+18.74%
13,371,00020,693,00023,168,00030,147,00024,272,00012,751,00020,198,64236,059,51032,034,8135,557,0004,015,5925,127,156-115,318,22344,414,62529,240,8675,995,383-72,203,90543,556,72950,525,32159,996,148
CFO
47m
P
1,594,00021,335,00018,133,00021,445,000-20,005,000105,20187,446,000-6,648,00089,542,00049,269,00070,602,00023,169,000119,469,00041,526,00073,428,00099,655,000-124,406,00043,738,000-39,586,00047,158,007
Dividend
Jan 09, 20260.014 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating from Zhengzhou, China, Henan Taloph Pharmaceutical Stock Co., Ltd. specializes in the research, development, production, and sale of a wide array of Chinese and Western medicines across the nation. The company's product line encompasses various forms, such as oral liquids, tablets, capsules, and injectable fluids. Notable products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, and pazufloxacin mesylate sodium chloride injections, alongside a selection of other infusion products. Taloph Pharmaceutical serves a diverse client base, including hospitals, pharmacies, and direct consumers. It was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd.
IPO date
Nov 05, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT